CanSino Biologics is technically leading the pack of SARS-CoV-2 vaccine developers with its investigational Ad5-nCoV leveraging its adenovirus-based viral vector vaccine platform. As of this writing, Phase II trials had already commenced in China.  In fact, TrialSite...